SCHEMBL4333501

SCHEMBL4333501

Cc1ncccc1C#Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
HPGD P15428 2/20 0.47
CYP2C19 P33261 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
HSD17B10 Q99714 1/20 0.47
APP P05067 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.45
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
GRM5 P41594 4/20 0.42
RAB9A P51151 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31673277 0.84 GRM5 (0.51) CYP1A2CYP3A4CYP2C9CYP2C19GRM5
SCHEMBL14676563 0.78 FFAR1 (0.58) PTGDR2FFAR1
SCHEMBL29994280 0.78 PTGDR2 (0.41) NPC1SMN1; SMN2ALDH1A1CYP1A2CYP3A4
SCHEMBL14434021 0.78 PTGDR2 (0.41) NPC1SMN1; SMN2ALDH1A1CYP1A2CYP3A4
SCHEMBL14975683 0.77 FFAR1 (0.60) NPC1SMN1; SMN2KDM4EMEN1ALDH1A1
SCHEMBL18952028 0.77 MAPT (0.57) NPC1SMN1; SMN2KDM4EMEN1ALDH1A1
SCHEMBL711130 0.74 PTGDR2 (0.40) NPC1KDM4EMEN1ALDH1A1CYP1A2
SCHEMBL7937991 0.74 NPC1 (0.44) NPC1SMN1; SMN2KDM4EMEN1ALDH1A1
Benzene SCHEMBL1653213 0.74 GRM5 (0.41) NPC1ALDH1A1HPGDPTGDR2GRM5
SCHEMBL2114742 0.73 APP (0.75) NPC1SMN1; SMN2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325964-A1 Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression WYETH (US) 2009-12-31 US claimed
WO-2009143404-A1 PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION WYETH (US) 2009-11-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325964-A1 Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression GRM5, GRIK5, GRM1 NPC1 3357/4885SMN1; SMN2 3956/4885KDM4E 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.